Biological therapy in systemic lupus erythematosus. - Wikidata - awgldk - TriplyDB

Biological therapy in systemic lupus erythematosus.

Biological therapy in systemic lupus erythematosus.

http://www.wikidata.org/entity/Q42141973

about

An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus Carbamylation of immunoglobulin abrogates activation of the classical complement pathway.Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.In-/off-label use of biologic therapy in systemic lupus erythematosus.Cutaneous manifestations of systemic lupus erythematosus.Drugs in early clinical development for Systemic Lupus Erythematosus.Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.The use of monoclonal antibodies to treat Castleman's disease.Update on Biologic Therapies for Systemic Lupus Erythematosus.Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus.Generation of systemic lupus erythematosus-specific induced pluripotent stem cells from urine.Association between vitamin D, oestradiol and interferon-gamma in female patients with inactive systemic lupus erythematosus: A cross-sectional study.

P2860

Q28074348-B28C594D-E0BD-43BB-BBB5-834BB5EC9064 Q34516987-894856C7-FD57-46EB-BAF6-2F3B6E789285 Q35031692-0B855798-6F6C-4B77-9DA8-963F429FC934 Q35094536-F3844589-C16D-4E5C-AF97-1465E55016F0 Q36134951-5CB623E5-3019-469A-A679-F856156C2D12 Q37324772-E4198279-88FE-426D-90DB-22064474B07E Q38108851-4F296A4E-19E4-4BD1-B570-D38B527A42A3 Q38184651-ACD36EF8-0CD7-40F6-94FB-B04EC7E3866D Q38864797-BCA0B2E8-73EA-466D-902A-D5076DBC078C Q40621351-237E3F8C-C9E4-423F-A054-6D9EB90B5D21 Q41417103-E98FCBD4-E8E5-4F6F-A627-3F65E7FCCD01 Q45885275-06D94B7F-DA97-47D3-A5CB-397E1BBACB95 Q47565730-57772B88-991C-4E4D-8635-EB0E5CF7A9DE

P2860

Biological therapy in systemic lupus erythematosus.

http://www.wikidata.org/entity/Q42141973

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Biological therapy in systemic lupus erythematosus.

@en

Biological therapy in systemic lupus erythematosus.

@nl

type

label

Biological therapy in systemic lupus erythematosus.

@en

Biological therapy in systemic lupus erythematosus.

@nl

prefLabel

Biological therapy in systemic lupus erythematosus.

@en

Biological therapy in systemic lupus erythematosus.

@nl

P1433

Q42141973-8EE5C5FD-4B2B-4225-9D46-390DF5994851

P1476

Q42141973-4E18C36B-91E6-4D0B-95E7-E62F10B3A5E0

P2093

Q42141973-4B9F2033-4562-4EFB-B23F-F2125BA09D6A

Q42141973-5837C107-4F2D-41FA-92E7-CC366819F112

Q42141973-E9A5D317-E123-4291-B12D-0523E42C6405

P2860

Q42141973-01035880-BB56-4BEA-8F2C-FDACFEB57554

Q42141973-0151463B-14DD-4B42-8A71-5FBD75D5EF76

Q42141973-03490815-8331-4F56-9134-95ACD1B4E1DB

Q42141973-0455397F-2382-454F-89C8-B4B0FB0711EC

Q42141973-114D2CB8-8F35-4883-9F07-080AEEBAA677

Q42141973-116752EF-637C-463D-AF7B-B8F895503DF0

Q42141973-12278DA0-060D-402E-B4B7-F64A421F47BC

Q42141973-14A6213E-742B-42AC-B7AA-842A66D5CAF3

Q42141973-1C64A656-7B60-4316-BCC1-D0884070E58A

Q42141973-2216AFE6-8F00-4C56-A373-11A9F665358F

P304

Q42141973-CF51E502-4FDD-4ECC-B84D-E2EB579CAB27

P31

Q42141973-75A0BAFE-D205-4F80-A221-0DD972F288FA

P356

Q42141973-A708B92C-1317-488D-9622-1D0EB24CDAF1

P478

Q42141973-A9D35369-C02E-417A-87FA-6CC265937D03

P577

Q42141973-B39FC673-D112-4986-A446-27DE5FAAEB53

P5875

Q42141973-53C498B6-FC4C-45B1-A1E1-27FBEB7A69C8

P698

Q42141973-8F0AD866-DC08-4FED-B5F5-E119673646AF

P932

Q42141973-A89797F9-B38F-4EAB-841F-16F37AA50C78

P356

P1433

International journal of rheumatology

P1476

Biological therapy in systemic lupus erythematosus.

@en

P2093

Lilian Tl Costallat

http://www.w3.org/2001/XMLSchema#string

Mariana Postal

http://www.w3.org/2001/XMLSchema#string

Simone Appenzeller

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in rheumatology: new targeted therapeutics

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria

CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice.

Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease.

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

P304

578641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/578641

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224006655

http://www.w3.org/2001/XMLSchema#string

P698

22500177

http://www.w3.org/2001/XMLSchema#string

P932

3303577

http://www.w3.org/2001/XMLSchema#string